Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub‐analysis of ODYSSEY COMBO II

AIM: This sub‐analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in high cardiovascular risk patients with or without diabetes mellitus (DM) receiving maximally tolerated statin therapy. METHODS: COMBO II was...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiter, Lawrence A., Zamorano, José Luis, Bujas‐Bobanovic, Maja, Louie, Michael J., Lecorps, Guillaume, Cannon, Christopher P., Handelsman, Yehuda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485164/
https://www.ncbi.nlm.nih.gov/pubmed/28206704
http://dx.doi.org/10.1111/dom.12909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485164/
https://www.ncbi.nlm.nih.gov/pubmed/28206704
http://dx.doi.org/10.1111/dom.12909

Ejemplares similares